Wellington Management Group
ARQT icon

Wellington Management Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Wellington Management Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
41,380
-2,993
-7% -$69.7K ﹤0.01% 1733
2026
Q1 		$1.05M Sell
44,373
-1,815
-4% -$46.3K ﹤0.01% 1665
2025
Q4 		$1.34M Sell
46,188
-201
-0.4% -$5.15K ﹤0.01% 1668
2025
Q3 		$874K Buy
46,389
+2,122
+5% +$33.5K ﹤0.01% 1801
2025
Q2 		$621K Sell
44,267
-2,373
-5% -$33.3K ﹤0.01% 1785
2025
Q1 		$729K Sell
46,640
-2,627
-5% -$37K ﹤0.01% 1768
2024
Q4 		$686K Sell
49,267
-3,882
-7% -$42.5K ﹤0.01% 1785
2024
Q3 		$494K Buy
53,149
+923
+2% +$9.11K ﹤0.01% 1818
2024
Q2 		$486K Buy
52,226
+5,679
+12% +$51.4K ﹤0.01% 1782
2024
Q1 		$461K Buy
+46,547
New +$347K ﹤0.01% 1817

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Wellington Management Group's ARQT Position: Q2 2026 in Review

Wellington Management Group reduced its Arcutis Biotherapeutics (ARQT) stake by 6.7% in Q2 2026, selling an estimated $69.7K and leaving 41,380 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1733.

Wellington Management Group first reported a position in ARQT in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.34M in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Wellington Management Group held 41,380 shares of Arcutis Biotherapeutics worth $1.08M as of Q2 2026.
  • Wellington Management Group sold 2,993 Arcutis Biotherapeutics shares in Q2 2026, an estimated $69.7K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1733 holding.
  • Wellington Management Group first reported a position in Arcutis Biotherapeutics in Q1 2024 and has held it in 10 quarters since.
  • Wellington Management Group's Arcutis Biotherapeutics position peaked at $1.34M in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.